[Clinical behavior of serous and mucinous borderline tumors of the ovary with diploid DNA stem line. Follow-up studies after organ preserving and non-organ preserving therapy].
Even today, the situation is still unclear with regard to the radicality of the operation and any adjuvant therapy required in treatment of borderline tumors of the ovary. In the last two decades, treatment of these tumors in the Department of Gynecology and Obstetrics at our hospital has depended on the stage of the disease and the age of the patient. It ranged from laparoscopic cyst extirpation to hysterectomy with bilateral adnectomy and omental resection and regional lymphnodectomy. From the end of 1985 to the end of 1992, 35 patients with borderline tumors of the ovaries were operated on. Histologically, 14 borderline tumors were mucinous, 21 were serous. A follow-up investigation was carried out five to 11 years after primary operation. In this period, no patient died of borderline tumor. Twenty-eight patients who were followed up were clinically free of recurrence, five patients are alive, but could not be followed up. Two patients have died of other diseases after five years. Only one patient received adjuvant chemotherapy. She could not be followed up. In the meantime, peritoneal implants were demonstrated at second-look laparoscopies in four out of 18 patients. Later, these could no longer be demonstrated (one patient) or did not affect the survival time (three patients) and thus ultimately was not pathologically relevant. Primarily, two of these four patient had stage Ia-Ic. The paraffin blocks of the preparations are still available from 26 patients, and additional investigations could be carried out. Nineteen percent of the borderline tumors showed micropapillary structures of an MPCS (= micropapillary serous carcinoma), which evidently did not have a negative effect on the prognosis. All borderline tumors showed diploid distributions in DNA cytometry. It is not possible to make a definitive treatment recommendation on the basis of this investigation because the number of patients followed up was too small.
Mecke
H
H
Geburtshilflich-Gynäkologische Abteilung, Auguste-Viktoria-Krankenhaus, Berlin.
Börner-Klaussner
B
B
Grosse
G
G
Nadjari
B
B
Hauptmann
S
S
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D018282:Cystadenocarcinoma, Mucinous / Q000235:genetics / Q000473:pathology / Q000601:surgery*; D018284:Cystadenocarcinoma, Serous / Q000235:genetics / Q000473:pathology / Q000601:surgery*; D004273:DNA, Neoplasm / Q000235:genetics*; D004171:Diploidy; D005260:Female; D005434:Flow Cytometry; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy; D010535:Laparoscopy; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000235:genetics / Q000473:pathology / Q000601:surgery*; D010052:Ovariectomy; D010053:Ovary / Q000473:pathology; D011230:Precancerous Conditions / Q000235:genetics / Q000473:pathology / Q000601:surgery*; D011379:Prognosis; D012086:Reoperation
D004273:DNA, Neoplasm
Zum klinischen Verhalten von serösen und muzinösen Borderline-Tumoren des Ovars mit diploider DNA-Stammlinie. Verlaufsbeobachtungen nach organerhaltender und nicht-organerhaltender Therapie.